Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088869 | 0.84 | TAAR1 (0.31) | MAOAALDH1A1SMN1; SMN2TAAR1L3MBTL1 | |
| SCHEMBL14809988 | 0.78 | CYBB (0.33) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17529811 | 0.77 | ACHE (0.38) | ANPEPMAOAMAOBALDH1A1F2R | |
| SCHEMBL2490256 | 0.76 | ALDH1A1 (0.39) | ALDH1A1GRM2TAAR1 | |
| SCHEMBL4608738 | 0.73 | LMNA (0.33) | ANPEPALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL17529702 | 0.72 | CA1 (0.44) | ANPEPALDH1A1KMT2AHTTTAAR1 | |
| SCHEMBL4717661 | 0.72 | DPP4 (0.35) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8093265 | 0.72 | ALDH1A1 (0.39) | ANPEPALDH1A1GAAKMT2A | |
| SCHEMBL14603853 | 0.70 | ALDH1A1 (0.37) | ANPEPMAOAMAOBALDH1A1TAAR1 | |
| SCHEMBL17529755 | 0.69 | TRPA1 (0.35) | MAOAMAOBATMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216599-A1 | Synthesis of diphosphinoarenes | HILLHOUSE JOHN HENRY (CA) | 2003-11-20 | — | — | US | disclosed |
| EP-1284980-A1 | SYNTHESIS OF DIPHOSPHINOARENES | CYTEC TECHNOLOGY CORP. (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001092275-A1 | SYNTHESIS OF DIPHOSPHINOARENES | CYTEC TECHNOLOGY CORP. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216599-A1 | Synthesis of diphosphinoarenes | PFAS, DDT, CDK8 | ANPEP 2716/4885MAOA 694/4885MAOB 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.